Braveheart Bio, Inc. Common Stock (BRVE)

US · Healthcare · Biotechnology

$18.60+6.80%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-15.0M

EPS

$-2.51

EPS estimate

$-0.25

EPS came in at -2.51 against a street estimate of -0.25 — a miss of 904.0%.

Market cap

$1.94B

Forward P/E

0.0

P/B

0.00

Book value

$-12.73

EPS (TTM)

$-6.08

52-week high

$32.00

52-week low

$17.86

50-day MA

$23.52

200-day MA

$24.23

Analysts rate Braveheart Bio, Inc. Common Stock a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $45.25.

Insiders

58.16%

Institutions

28.19%

Document	Date
Quarterly report · Q2 2026 BRAVEHEART BIO, INC. – FORM 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash position: $122.8 million as of June 30, 2026 (up from $89.2 million at De	2026-09-08
Results announced · Q3 2026 BRAVEHEART BIO Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash and cash equivalents: $122.8 million as of June 30, 2026; $527.3 million on	2026-09-08
Charter / bylaws change · Q3 2026 BRAVEHEART BIO, INC. - 8-K SUMMARY HEADLINE NUMBERS • IPO completion date: August 5, 2026 (earliest event reported) • Stock ticker: BRVE on Nasdaq G	2026-08-07

Readable in the app.

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Braveheart Bio, Inc. Common Stock — free to start.

Data updated 2026-11-07.